Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Weighted Average and Diluted) (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.98 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 10.11% to -$0.98 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.69, a 23.83% decrease, with the full-year FY2025 number at -$3.69, down 23.83% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.98 for Q4 2025 at Kymera Therapeutics, down from -$0.94 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.25 in Q4 2023 to a low of -$0.98 in Q4 2025.
  • A 5-year average of -$0.73 and a median of -$0.71 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 57.63% in 2023, then tumbled 256.0% in 2024.
  • Kymera Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.67 in 2021, then rose by 11.94% to -$0.59 in 2022, then skyrocketed by 57.63% to -$0.25 in 2023, then crashed by 256.0% to -$0.89 in 2024, then fell by 10.11% to -$0.98 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EPS (Weighted Average and Diluted) are -$0.98 (Q4 2025), -$0.94 (Q3 2025), and -$0.95 (Q2 2025).